Webinar Date/Time: Wed, Feb 28, 2024 11:00 AM EST
RT-qPCR is a rapid and sensitive bioassay designed to detect subtle gene expression changes, crucial for evaluating the potency of therapeutic biological products. Join Catalent’s webinar to learn how this technique enhances drug potency analysis, streamlining the evaluation of cell response to ligands and transgenic vectors.
Register Free: https://www.pharmtech.com/pt_w/novel-biological-responses
Event Overview:
Transcriptional activity within a cell can be used to evaluate cell response to a ligand or promoter activity within a transgene or plasmid within a cell. Catalent has developed a relative potency bioassay using real-time quantitative reverse transcription (RT-qPCR) in a duplex format to assess relative transcription activity in cells treated with ligands or transgenic vectors. The assay utilizes two fluorescent dyes with minimally overlapping emission spectra that allow real-time monitoring of the gene expression of both target and normalizer genes. Notably, the assay simplifies the process by eliminating the need for mRNA purification, enabling more efficient and accurate analysis. Normalizing the qPCR cycle thresholds (CT) of the target transcript to the reference transcript allows the response curve to be generated and compared to a reference standard. The generation of a four-parameter fit curve analysis from raw qPCR cycle threshold data allows for the comparison of relative potency and assessment of suitability based on curve parallelism. Catalent has successfully implemented this assay platform to develop a reliable, accurate, and specific bioassay. It stands out for linear response and reproducibility, making it a valuable tool for evaluating the relative potency of various test substances. Join us to explore how these robust cell-based potency assays can enhance your research and provide critical data on drug product potency.
Key Learning Objectives:
Who Should Attend:
Speaker:
Pedro Morales
Director, Biologics Analytical Services
Catalent
Pedro Morales joined Catalent in 2007 and is currently a director of Biologics Analytical Services. He oversees cell-based and non-cell based functional assays, including analytical process impurities, at Catalent’s Kansas City location. He has over 30 years of experience supporting biologics analytical sciences, with previous roles at Aptuit and the University of Kansas. Pedro received his Masters in Biochemistry and Molecular Biologics at the University of Austral Chile.
Register Free: https://www.pharmtech.com/pt_w/novel-biological-responses
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.